Cabozantinib for recurrent or worsening meningioma tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a meningioma diagnosis confirmed by biopsy (preferred) or imaging, and any grade is allowed (I, II, or III).
- Your meningioma has returned or is growing after standard treatment was done more than 6 months ago (or you couldn’t get that treatment).
- Your body is strong enough for treatment: your Karnosfky score is at least 50.
- Your blood, kidney, and liver tests meet safety limits (including specific minimum counts and organ function thresholds).
- Your tumor can be measured on scans, and your doctor can use RANO meningioma criteria to track it.
- You can take pills safely and have no major heart rhythm, bleeding, infection, or serious unhealed-wound problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
This trial tests abemaciclib, a targeted medicine, to see if it can help people with newly diagnosed grade 3 meningioma after standard radiation treatment. It may help by slowing tumor growth or improving outcomes after initial therapy.
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.